Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.

The oral presentation was given by Christopher D. Roberts, Ph.D., Director of Medicinal Chemistry at Genelabs, entitled "GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties."

GL59728 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs. In the presentation, Dr. Roberts outlined the lead optimization of certain non-nucleoside HCV polymerase inhibitors through an iterative process involving testing for potency in directly inhibiting HCV NS5b polymerase, inhibiting the replication of an HCV sub-genomic replicon, and pharmacokinetic properties.

The optimized lead that emerged from this chemistry approach, one of several taken by Genelabs, is known as GL59728. The IC50 of GL59728 for inhibition of the HCV NS5b polymerase is 16 nanomolar and the EC50 for inhibition of HCV replicon is 170 nanomolar. Further, GL59728 shows excellent oral bioavailability, exceeding 50% in all four species tested, including higher-order species, low clearance and a half-life consistent with once- or twice-daily dosing. The tissue distribution of GL59728 also appears favorable; since its concentration is enhanced several fold in liver, the site of HCV infection, relative to that obtained in plasma. Importantly, GL59728 was also tested in combination with other classes of HCV antiviral compounds, including a nucleoside chain terminator, a protease inhibitor and interferon alpha, and shown to be additive in activity with each.

In June 2006 Genelabs entered into a license and research co
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  Halozyme ... announced that the U.S. Food and Drug Administration ... enrollment and dosing of PEGPH20 in SWOG,s ongoing ... designed to evaluate Halozyme,s investigational drug PEGPH20 (PEGylated ... chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.  ...
(Date:9/18/2014)... -- Australian biomarker discovery company Minomic International Ltd will ... prostate cancer screening test, planning to achieve US Food ... Minomic,s proprietary MiStat™ technology is a screening assay ... known as the MIL-38 antigen. This biomarker is present ... Researchers at 11 leading urology centres in ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... , BEDFORD, Mass., Aug. 19 Holo ... (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of ... healthcare needs of women, today announced the publication of the first of ... both symptomatic and asymptomatic pregnant women at risk for preterm birth. The ...
... , JAMESBURG, N.J., Aug. 19 Phytomedics Inc. today ... 2b clinical trial with an extract of Tripterygium wilfordii Hook F ... in the August 18, 2009 issue of the Annals of Internal ... article entitled "Comparison of Tripterygium wilfordii Hook F versus ...
Cached Medicine Technology:Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 2Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 3Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 4Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis 2Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis 3
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is proud ... Physicians Association (HPA) Friends and Family Golf tournament ... The tournament, which will take place at TopGolf from ... scholarships through three golf challenges, “Top Scramble”, “Top Score”, ... is provided at the event and there will be ...
(Date:9/18/2014)... 18, 2014 After years of shooting at ... firing range berms were saturated with lead, which increased the ... in the berm and send metal fragments back at the ... splashback, and the greater the potential for injury to officers. ... to remove lead from the range environment. , ...
(Date:9/18/2014)... 18, 2014 Sutter Health’s California Pacific ... of Dolby Laboratories, by naming the Ray Dolby Brain ... Ray Dolby provided a founding gift of $21 million ... provides services to patients and families suffering from Alzheimer’s, ... have been treated at the center since its opening ...
(Date:9/18/2014)... On August 23, the HearStrong Foundation ... Service Award for his contributions to the deaf and ... Retired Players Association (NBRPA) Legends World Sports Conference in ... in 1977, Glenn would go on to play for ... Hawks, and the Milwaukee Bucks throughout his ten-year career ...
(Date:9/18/2014)... MD Complete , the breakthrough ... prescription, announced today that SHAPE Magazine has named ... Peel” in its annual Beauty Awards. The issue is ... products as tested by SHAPE’s expert team. , SHAPE ... Among the thousands of beauty products launched every year, ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:Firing Range Safety is Ohio DOC Priority 2Health News:Firing Range Safety is Ohio DOC Priority 3Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 2Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2
... Accounts; Membership in ECP Global Communication International NetworkNEW ... www.feintuchcommunications.com ), a strategic relations firm ... Feintuch, has opened for business with offices at ... http://www.newscom.com/cgi-bin/prnh/20090406/NY94367LOGO )Mr. ...
... for Medical Benefits, Movement to Direct Contracting for ... HealthLeaders-InterStudyNASHVILLE, Tenn., April 6 HealthLeaders-InterStudy, the leading ... between January 2008 and July 2008 enrollment in ... with a pharmacy benefit manager (PBM), also known ...
... Michael Paddock, CEO of Grants Office, LLC and a ... for on-camera and telephone interviews.Over the past several months, ... of knowledge and resources relating to the American Recovery ... knowledge of the various facets of ARRA funding (in ...
... April 6 The Quantum Group, Inc. (NYSE Amex: ... a Healthcare Services Organization (HSO), announced today that PWeR(TM) ... information platform and IBM hosted solution, is presenting in ... and Management Systems Society) Conference. The HIMSS09 conference ...
... those diagnosed with autism have underlying medical disorders that ... improvementATLANTA, April 6 A child is diagnosed with ... is more common in American children than cancer, diabetes, ... Control (CDC) estimates that one in every 94 boys ...
... Breakthrough Study Led by USC and Mayo ... Older adults can significantly improve their memory and performance ... according to a study published today in The Journal ... of 487 healthy older adults was led by researchers ...
Cached Medicine News:Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 2Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 3Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 4Health News:Enrollment in Employer-Contracted Pharmacy Benefit 'Carve-Out' Increased by More than Six Million Lives 2Health News:Grants Office CEO Available for Media Interviews on Stimulus Funding 2Health News:PWeR(TM) Presenting at HIMSS Conference in Chicago 2Health News:PWeR(TM) Presenting at HIMSS Conference in Chicago 3Health News:PWeR(TM) Presenting at HIMSS Conference in Chicago 4Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Computerized Brain Exercise Improves Memory 2
Inquire...
... The Trinity Biotech Captia™ Mumps IgG ... the detection and quantitative determination of IgG ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
... AUTOMATION, INC. (DAI) Mumps IgG ... intended for the detection and ... to Mumps virus in human ... be used for the determination ...
... Corporation announced the launch of the ... first bi-directional cooled-tip catheter available in the ... offers physicians the benefits of cooled ablation ... the Boston Scientific Blazer(R) catheter platform. ,Cooled ...
Medicine Products: